

# Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway

Ursula Ehmer<sup>1,2,3</sup> and Julien Sage<sup>1,2</sup>

## Abstract

The control of cell division is essential for normal development and the maintenance of cellular homeostasis. Abnormal cell proliferation is associated with multiple pathological states, including cancer. Although the Hippo/YAP signaling pathway was initially thought to control organ size and growth, increasing evidence indicates that this pathway also plays a major role in the control of proliferation independent of organ size control. In particular, accumulating evidence indicates that the Hippo/YAP signaling pathway

functionally interacts with multiple other cellular pathways and serves as a central node in the regulation of cell division, especially in cancer cells. Here, recent observations are highlighted that connect Hippo/YAP signaling to transcription, the basic cell-cycle machinery, and the control of cell division. Furthermore, the oncogenic and tumor-suppressive attributes of YAP/TAZ are reviewed, which emphasizes the relevance of the Hippo pathway in cancer. *Mol Cancer Res*; 14(2): 127–40. ©2015 AACR.

## Introduction

A tight control of cell division is essential for the maintenance of homeostasis in adult organs and tissues. Several cellular mechanisms exist to regulate and fine-tune cell proliferation during physiologic growth and regeneration. Failures in one or more of these control mechanisms can result in unchecked cell divisions and, eventually, cancer development (1). A number of cellular pathways have been implicated in the regulation of cell division. In particular, the importance of the so-called "Hippo" signaling pathway in the control of proliferation was discovered a little more than 10 years ago in *Drosophila* (2, 3). Since then, it has become evident that the Hippo signaling pathway is involved in a plethora of cellular functions, ranging from organ size control to cellular differentiation and metabolism (4–7). However, the control of cell proliferation—mainly by negatively regulating the pathway's downstream effectors YAP and TAZ—remains one of its central functions (8). In this review, we provide a detailed overview of the role of the Hippo pathway in the control of proliferation and summarize recently published data that shed light on the molecular basis for Hippo-mediated cell-cycle control. Finally, we discuss the implication of these findings for our understanding of the role of Hippo signaling in cancer and for the development of novel tumor therapies.

<sup>1</sup>Department of Pediatrics, Stanford University School of Medicine, Stanford, California. <sup>2</sup>Department of Genetics, Stanford University School of Medicine, Stanford, California. <sup>3</sup>Department of Medicine II, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany.

**Corresponding Author:** Ursula Ehmer, Klinikum rechts der Isar, Technische Universität München, II. Medizinische Klinik und Poliklinik, Ismaninger Strasse 22, 81675 Munich, Germany. Phone: 49-89-4140-4982; Fax: 49-89-4140-4910; E-mail: ursula.ehmer@tum.de

doi: 10.1158/1541-7786.MCR-15-0305


©2015 American Association for Cancer Research.

## The Canonical Hippo/YAP Signaling Pathway: A Brief Overview

The first big steps in our understanding of Hippo pathway function were made in flies. Although many pathway functions are conserved between flies and mammals (9), for historic reasons, mammalian and *Drosophila* orthologues differ in their respective names. With few exceptions, we use here the mammalian nomenclature and focus on mammalian systems. This should by no means make the major advances in the *Drosophila* field less important.

The backbone of the Hippo signaling pathway consists of a kinase cascades that works to control the activity of the downstream effectors YAP and TAZ. The upstream kinases of the Hippo signaling pathway, MST1 and MST2, work together with the adaptor protein SAV1/WW45 to phosphorylate and activate LATS1 and LATS2. The activated LATS kinases together with MOB1 then phosphorylate the YAP and TAZ effector proteins (Fig. 1). This phosphorylation event results in the nuclear exclusion of YAP/TAZ mediated by 14-3-3 proteins and, ultimately, their cytoplasmic degradation (5, 10). However, not all cytoplasmic YAP/TAZ is degraded and the phosphorylated, cytoplasmic proteins can associate with protein complexes of other pathways such as WNT or TGF $\beta$  signaling to modify signaling through these pathways (11, 12). Nevertheless, the main functions of YAP and TAZ can be attributed to their unphosphorylated, nuclear state, where the proteins function as transcriptional cofactors that can interact with several transcription factors. Their major transcriptional binding partners are members of the TEAD/TEF transcription factor family (TEAD1-4) that are believed to mediate the majority of pro-proliferative and oncogenic functions of YAP and TAZ (13).

Apart from so-called "canonical" Hippo signaling, several cellular components independent of the classic pathway can control YAP and TAZ. Importantly, the differential regulation is likely tissue specific (14). Particularly, the requirement of all



**Figure 1.** An overview of the regulation of transcription by YAP/TAZ transcriptional cofactors and the regulation of YAP/TAZ activity in mammalian cells. YAP/TAZ are downstream mediators of numerous signaling pathways in cells, including from the cell surface. Their transcriptional targets have been involved in the regulation of proliferation and growth, but also cell death and differentiation.

kinases of the core Hippo kinase cascade in the control of YAP and TAZ activity does not seem to be conserved in all mammalian cell types. Although MST1/2 control the phosphorylation of YAP in the liver, the function of the upstream Hippo kinases is dispensable for YAP activation in mouse embryonic fibroblasts, keratinocytes, and possibly also melanocytes (15–17). Furthermore, the functional requirement of either YAP or TAZ varies between different cell types. Although many studies specifically highlight the role of YAP in tumorigenesis—or consider YAP and TAZ as functionally redundant—at least in some cancers such as breast cancer, melanoma, or glioblastoma, TAZ may play a more important role (18–20).

### Cellular Functions of Hippo Signaling

In many tissues, YAP and TAZ regulate key cellular functions that include—but are not limited to—proliferation control, inhibition of apoptosis, and promotion of metastasis (2, 3, 18, 21). By negatively regulating oncogenic YAP and TAZ activities, the kinases of the Hippo pathway work as important tumor-suppressive molecules. In many cancers, Hippo signaling is dysfunctional and activation of YAP and/or TAZ is observed, with high levels of nuclear proteins; in addition, direct genetic mutations in Hippo pathway genes are not very frequent, with the exception of *NF2* (reviewed in ref. 22). This unique mutation pattern for *NF2* could

Downloaded from <http://aacrjournals.org/mcr/article-pdf/14/2/127/181751/127.pdf> by guest on 20 May 2025

either suggest that loss of NF2 function results in additional oncogenic effects beyond inactivating Hippo signaling; alternatively, there may be an optimal level of altered Hippo pathway activity to promote cancer development and losing NF2 may achieve this oncogenic level in cancer cells. Activation of Hippo/YAP signaling can also be achieved through alterations in many of the pathways that functionally interact with Hippo signaling (see below), which again may lead to just enough perturbation in the pathway to be oncogenic. Nevertheless, more and more genetic and genomic alterations are being discovered in Hippo pathway members, including amplification of the YAP gene (23, 24) or gene fusion events involving multiple pathway members (25); it is also possible that a number of epigenetic events lead to silencing of tumor-suppressive elements in the pathway (26).

Aside from its role in cancer, the physiologic role of Hippo signaling is no less important: by being involved in the maintenance of tissue specific stem cells, tissue regeneration, wound healing as well as in the control of differentiation (6, 27–33), this pathway is a major player in the control of embryonic development and tissue homeostasis. YAP-deficient mouse embryos die at E8.5 with multiple developmental defects (34). Knockout of Mst1/2 or Sav1 results in liver overgrowth and the development of hepatocellular carcinoma (35, 36), a phenotype that is also observed in transgenic mice overexpressing YAP (4, 37). However, organ size control only presents one outcome of deregulated Hippo signaling. The direct effects of unleashed YAP/TAZ activation are tissue and often cell-type specific, but the control of cell proliferation remains a common theme. Interestingly, progenitor cell compartments seem to be especially sensitive to the loss of Hippo control mechanisms, including in the liver (36, 37), the intestine (37, 38), the nervous system (39), the skin, and the lung (40). Several studies further indicate that YAP and TAZ are involved in the maintenance of a stem cell phenotype and can inhibit cellular differentiation (6, 27, 32, 41, 42). Key functions for the Hippo signaling in the biology of stem/progenitor cells include the regulation of cell cycle and interactions with other signaling pathways (e.g., Hedgehog, Wnt, or Notch; see below). In addition, this control of stem cells by Hippo/YAP signaling can be achieved in a cell-intrinsic manner but also by controlling the stem cell niche, as has been described in flies (43) and in mammals (44).

Keeping the balance between promotion of physiologic proliferation and prevention of unrestricted cell divisions that lead to cancer development is a key function of Hippo signaling and makes it a promising therapeutic target in many human pathologies. For instance, promotion of downstream YAP or TAZ activity could be useful to promote tissue regeneration; in contrast, strategies to activate or Hippo signaling or inactivate YAP/TAZ may help treat certain cancers (Fig. 2).

## Regulation of Hippo Signaling


The core Hippo kinase cascade functions as a central hub that relays input from the "outside world" of the cell and translates it into specific cellular responses by controlling the activity of downstream YAP/TAZ and by interacting with other pathways such as Wnt/ $\beta$ -catenin, Notch, AKT, or Hedgehog signaling (45–50). Although the regulation by extracellular receptors is shared by many signaling pathways, Hippo signaling seems to be especially sensitive to input from mechanical cues. How signals from

beyond the cell's borders feed into the Hippo signaling cascade has been extensively studied over the recent years and is reviewed in detail elsewhere (14). Below, we provide an overview of the most important regulators.

The long quest to find receptors that directly activate or inactivate Hippo signaling only recently led to the identification of G-protein-coupled receptors (GPCR) as regulators of this pathway (51, 52). GPCRs are integral membrane receptors that are activated by external ligands whose binding leads to activation of the alpha-subunit of one or more of the four subclasses of G proteins  $G_{\alpha i/0}$ ,  $G_{\alpha 12/13}$ ,  $G_{\alpha s}$ , and  $G_{\alpha q/11}$ . In the regulation of Hippo signaling, activation of GPCRs linked to  $G_{\alpha s}$  results in the phosphorylation of LATS and therefore inactivation of YAP. On the other hand, activation of  $G_{\alpha 12/13}$ -coupled GPCRs is correlated with inhibition of LATS and activation of YAP (51). Additionally, a role for mutated  $G_{\alpha q/11}$  in uveal melanoma carcinogenesis mediated by YAP has been reported (53). How GPCR signaling transduces into activation or inactivation of YAP is not well understood, but at least for some GPCRs these effects seem to be mediated by Rho GTPases and/or alterations in F-actin polymerization (51, 52, 54). Targeting this large class of cell-surface receptors may be a promising approach to modify Hippo pathway activity in cancer or regeneration.

Other membrane receptors that have been shown to regulate YAP expression and proliferation are the receptor tyrosine kinases EGFR and ERBB4. Treatment with EGF leads to EGFR-mediated activation of PI3K and PDK1, which connects to the Hippo pathway through the adaptor protein SAV1/WW45. PDK1 activation triggers the dissociation of the Hippo core kinases from the scaffolding protein SAV1/WW45 and results in inactivation of LATS, dephosphorylation and nuclear translocation of YAP, and expression of YAP target genes (55, 56). Interestingly, one of the YAP targets identified is the EGFR ligand amphiregulin (AREG), providing a positive feedback loop between YAP and EGFR signaling that can work to amplify proliferative signals from both signaling pathways and also trigger cell proliferation in a non-cell-autonomous manner (57). Another member of the EGR receptor family, ERBB4, has been shown to trigger YAP activation and expression of YAP target genes through direct interaction of its soluble intracellular domain with YAP and possibly also TEAD1 in the nucleus (58). Most likely, future research will identify additional receptors that feed signals into the Hippo signaling cascade. Manipulating these receptors to specifically alter Hippo signaling will then present the next big challenge.

In addition to receptor-mediated regulation, the Hippo signaling pathway receives multiple "mechanical" inputs from the cell surface as well as from within the cell (reviewed in refs. 59, 60). The mechanical cues involved in the regulation of Hippo signaling include proteins that bind to intercellular junctions such as tight and adherence junctions as well as components of the cytoskeleton, including F-actin, microtubules, actomyosin, and possibly centrosomes (61–66). Specifically, the interactions with centrosomes may also be relevant to the regulation of cell-cycle progression by Hippo signaling. It is highly likely that these biomechanical regulators are also involved in the promotion of oncogenic YAP and TAZ activity in cancer. It is tempting to speculate that changes of the extracellular matrix found in cancer (67, 68) might influence cell proliferation through mechanical regulation of Hippo pathway effectors (59, 69). Additionally, components of the cytoskeleton are often deregulated in cancer cells, which could possibly contribute to the activation of YAP/



**Figure 2.** Oncogenic and tumor-suppressive functions of YAP and TAZ in human cancer (86, 151, 162). See text for details.

Downloaded from <http://aacrjournals.org/mcr/article-pdf/14/2/127/181751/127.pdf> by guest on 20 May 2025

TAZ in carcinogenesis. In cancer-associated fibroblasts, matrix stiffening enhances YAP activation—which in turn promotes expression of cytoskeletal regulators involved in remodeling of the extracellular matrix (69). Additionally, the connection of intercellular junction-associated proteins to the Hippo pathway seems to be essential for the maintenance of apical–basal cell polarity (14). Several well-established upstream regulators of Hippo signaling, such as Merlin, Kibra, Expanded, the Angiomin proteins, E-cadherin, and  $\alpha$ -catenin, are known to associate with tight and adherence junctions or other cell polarity complexes (16, 70–73). Alterations in this regulatory network may be

linked to the disruption of cell polarity that is linked to cancer progression and invasiveness (74).

One of the best-studied upstream regulators of the Hippo signaling pathway is the apical membrane protein NF2/Merlin—a well-described tumor suppressor inactivated in many cancers (75). In mammals as well in flies, NF2/Merlin can interact with the Hippo signaling pathway on multiple levels (reviewed in ref. 75). Importantly, Merlin directly binds and recruits the LATS kinases to the plasma membrane to promote their phosphorylation and activation by MST1/2 and SAV1 (76). An additional mechanism to directly regulate LATS activity is mediated by

phosphorylated Merlin that inhibits the tumorigenic effects of the E3 ubiquitin ligase CRL4-DCAF1 in the nucleus (77). Bound by Merlin, CRL2-DCAF1 is not able to ubiquitinate and inactivate LATS1/2 to promote YAP activity (78). Furthermore, Merlin can bind to other cell membrane and junction proteins, such as Angiomotin and  $\alpha$ -catenin, and probably influences their interaction with the Hippo signaling kinases (reviewed in ref. 75). Interestingly, tumor development upon NF2 inactivation in the liver and other tissues is suppressed by heterozygous deletion of YAP, supporting the idea that NF2/Merlin inhibits proliferation by repression of YAP activity (79, 80).

The Angiomotin family of proteins AMOT (Angiomotin), AMOTL1 and AMOTL2 interact with tight junction proteins as well as the actin cytoskeleton and play an important role in the maintenance of cell polarity. With exception of the AMOT-p80 variant, all members of Angiomotin protein family can directly bind to YAP and TAZ and inhibit their activity, either by recruitment to the extranuclear environment or by inducing YAP/TAZ phosphorylation (72, 81, 82). Interestingly, several recent reports show that AMOT proteins themselves are targets of the LATS1/2 kinases (83, 84). Phosphorylation by LATS1/2 negatively regulates actin binding of Angiomotins and increases their ability to inhibit YAP (82, 84), providing an additional mechanism for LATS kinases to negatively regulate downstream YAP. Another connection between Hippo signaling and intercellular junctions is the adherence junction protein  $\alpha$ -catenin, which is able to directly bind and inhibit phosphorylated YAP by facilitating its sequestration in complex with 14-3-3 proteins (16). This mechanism restricts proliferation in several different cell types and seems important to mediate the tumor suppressor activity of  $\alpha$ -catenin (12, 16, 85).

Other cell junction proteins or proteins involved in the maintenance of apical–basal polarity such as SCRIB, PTPN14, LIN7C, PATJ, and MPDZ or E-cadherin, Crumbs, ZO1, ZO2, NPHP4, and LKB1, respectively, interact with the Hippo signaling cascade on different levels (reviewed in refs. 14 and 86).

Sensing inputs from neighboring cells, the extracellular matrix, or the cytoskeleton is key to trigger several cellular responses, but most importantly one decision—to grow and divide or to remain quiescent. Clearly, integration of these signals plays a key role in the activity of the Hippo signaling pathway. Failures in the translation of these cues from the outside world can be deleterious to the maintenance of tissue integration and furthermore underline the importance of tight control mechanisms in this process.

## The Many Nodes That Connect to Hippo Signaling

In addition to the multitude of upstream inputs to Hippo signaling there are several pathways that directly interact with the more downstream components of the signaling cascade to modify the output of Hippo signaling.

The most well-investigated partner of the Hippo pathway is the Wnt signaling pathway. Binding of WNT ligands to their receptors in the cell membrane results in phosphorylation of the  $\beta$ -catenin degradation complex. The phosphorylation of this complex upon Wnt activation, however, leads to stabilization of  $\beta$ -catenin and its translocation into the nucleus, where it associates with TCF transcription factors to promote the expression of WNT/ $\beta$ -catenin target genes (87). A large body of data now indicates that cytoplasmic YAP and TAZ can inhibit Wnt pathway activation—

mainly through interaction with the  $\beta$ -catenin destruction complex.

A first study that gave evidence for a connection between Wnt and Hippo signaling showed that phosphorylated, cytoplasmic TAZ binds to DVL, a member of the  $\beta$ -catenin degradation complex. TAZ binding inhibits the phosphorylation of DVL by CK1 $\delta/\epsilon$  upon Wnt activation, thereby stabilizes the  $\beta$ -catenin destruction complex and prevents the translocation of  $\beta$ -catenin into the nucleus (46). Interestingly, the  $\beta$ -catenin degradation complex also seems to be involved in the degradation of TAZ in the cytoplasm, as it mediates the interaction of phosphorylated TAZ with its ubiquitin ligase  $\beta$ -TrCP (88). Compelling evidence also indicates that both YAP and TAZ are integral components of the  $\beta$ -catenin destruction complex and are required for the overgrowth phenotype in APC-deficient intestines (11). In addition, phosphorylated YAP/TAZ can directly bind to  $\beta$ -catenin to suppress its nuclear translocation in colorectal cancer cells (89). A third mechanism by which cytoplasmic YAP can inhibit Wnt signaling output is by restricting DVL activity independent of the  $\beta$ -catenin degradation complex, likely through inhibition of the transcriptional coactivator function of DVL (44). This latter mechanism seems to be highly important to counterbalance activated Wnt signaling in regenerating intestinal stem cells, but also has implications in carcinogenesis as reexpression of previously silenced YAP can inhibit cell proliferation in xenograft models of an aggressive subtype of human colorectal carcinomas (44). These findings indicate that YAP might have important tumor-suppressive functions under certain conditions that are related to activated Wnt/ $\beta$ -catenin signaling. However, the role of YAP in cancers with activated  $\beta$ -catenin is not fully understood and likely highly context dependent: in a screen in  $\beta$ -catenin-activated cancer cell lines, YAP was essential for tumorigenicity (90). Mechanistically, YAP binds to the transcription factor TBX5 in a complex with  $\beta$ -catenin to induce the transcription of pro-oncogenic and antiapoptotic target genes independent of TCF transcription factors. The oncogenic activity of YAP may require nuclear translocation and likely relies on tyrosine phosphorylation by the YES protein kinase independent of canonical Hippo signaling (90). A similar interaction was observed in mice with cardiac deletion of Sav, where increased nuclear YAP was associated with cardiac overgrowth that was dependent on Wnt signaling (45). In chromatin immunoprecipitation assays, both YAP and  $\beta$ -catenin were shown to bind to common targets, such as *Snai2* and *Sox2*, to enhance their transcription and contribute to increased proliferation in cardiomyocytes (45). The contradicting findings on the interplay between YAP/TAZ and Wnt signaling show that multiple factors might influence the outcome observed in Wnt-activated cells. To understand the mechanisms that divert YAP/TAZ activity toward tumor suppression or oncogenesis presents a major challenge and will be of high importance for therapeutic targeting of Hippo signaling.

Long before LATS kinases were identified as the main regulators of YAP/TAZ activation, AKT was shown to phosphorylate YAP at Ser127, resulting in nuclear exclusion and degradation by 14-3-3 proteins similar to the effect observed after LATS-mediated phosphorylation (91). A recent publication indicates that YAP is able to promote PI3K–AKT signaling in cardiomyocytes by direct transcriptional activation of the catalytic PI3K-subunit p110 $\beta$  (92). This activation of AKT signaling is associated with increased survival and proliferation in cardiomyocytes and can at least in part explain the promotion of cardiac regeneration by YAP (93)

that is counteracted by overexpression of Mst1, resulting in dilated cardiomyopathy (94). Recently, a cross-talk between mTOR and YAP has been described in TSC1/2-mutant cells. In this system, hyperactive mTOR results in activation of YAP—most likely in an autophagy-dependent manner—to promote proliferation and tumor formation (95).

There is strong evidence that the Notch pathway is activated by YAP through direct transcriptional targeting of *JAG1* in the liver (27, 50). Additionally, high activity of YAP in Mst1/Mst2-deficient intestinal epithelial cells correlates with activation of Notch signaling (96). Although these findings indicate that Notch signaling is downstream of Hippo/YAP, the two pathways can also act in concert by regulating expression of CDX2 in the trophectoderm (97). Notch signaling can also inhibit the *Drosophila* homolog of the YAP/TAZ-TEAD complex—Yki/Sc—under specific conditions (98). Therefore, the interaction between Hippo and Notch signaling is likely context dependent and further research is needed to investigate the interaction between these two pathways.

A connection between Hedgehog signaling and YAP has been identified in medulloblastoma and neural precursors, where Sonic hedgehog (SHH) promotes nuclear accumulation of YAP and results in increased proliferation (49). On the other hand, activation of SHH inversely correlates with the expression of nuclear YAP in pancreatic adenocarcinoma (99). *Gli2*, a major transcriptional mediator of Hedgehog signaling, has been identified as a transcriptional target of YAP/TEAD in neural precursors (49), while YAP can bind to and inhibit GLI transcription factors in fibroblasts, resulting in decreased expression of Hedgehog pathway targets (99). Importantly, Hippo upstream kinases as well as YAP/TAZ are involved in ciliogenesis of the primary cilium (100, 101), an organelle of the plasma membrane that is an important determinant of Hedgehog signaling (and other signaling pathways). These findings indicate that the interaction between Hippo and Hedgehog signaling is highly complex and tissue- as well as context dependent.

In summary, the downstream effectors of Hippo signaling interact with many key pathways that play important roles in cell proliferation and also oncogenesis. In many cases, these interactions might contribute to the amplification of the proliferative output of YAP/TAZ signaling. As this pathway activation often seems to be dependent on the transcriptional activity of YAP/TAZ, it might be targetable by specific inhibition of YAP/TAZ-TEAD-mediated transcription. However, some interactions seem to function outside canonical Hippo signaling. Their role in cancer as well as possible means to target these interactions to inhibit proliferation or promote regeneration remain to be investigated.

### Fine-tuning YAP/TAZ Activity

The most important regulators of YAP/TAZ are LATS kinases. By phosphorylation at one or more serine residues, LATS1/2 negatively regulate the transcriptional activity of YAP and TAZ. In addition to LATS1/2, other proteins such as AKT and JNK can mediate YAP serine phosphorylation (91, 102). Phosphorylated YAP/TAZ proteins are retained in the cytoplasm, where they are targeted for degradation by 14-3-3 protein. Interestingly, YAP methylation by SET7 also results in cytoplasmic retention and decreased YAP transcriptional activity, a mechanism that seems to be of relevance in the maintenance of tissue homeostasis in the intestine (103). Another level of YAP regulation is mediated by

tyrosine phosphorylation by YES, SRC, or c-ABL kinases (90, 104–106). However, the biologic effects of tyrosine phosphorylation seem to be context dependent and can divert YAP transcriptional activity toward expression of pro- or antiapoptotic genes, respectively (90, 104).

Because phosphorylation presents such an important determining factor of YAP/TAZ activity, it is highly likely that one or more proteins exist that control their dephosphorylation. Recently, PP1A and PP2A have been identified as phosphatases of YAP and TAZ that promote nuclear translocation and expression of target genes (16, 107, 108). Further research is needed to determine the *in vivo* relevance of PP1A, PP2A, and other Hippo pathway phosphatases, including those interacting with kinases in the pathway (109–111). The search for phosphatases in the Hippo pathway is an area of active investigation that will give novel insights into the mechanisms regulating Hippo activity. Ultimately, inhibition of oncogenic phosphatases in the Hippo pathway could also provide new therapeutic options.

### Transcriptional Control of Proliferation


The range of biologic functions of the YAP and TAZ effector proteins we know about is ever expanding. YAP and TAZ can bind to several different transcription factors, each likely initiating transcriptional programs that contribute to the functional diversity of active YAP/TAZ (14). In general, transcription factor binding requires nuclear translocation of dephosphorylated YAP and TAZ. Upon phosphorylation by LATS as well as other kinases, YAP and TAZ are retained in the cytoplasm and become transcriptionally inactive, resulting in decreased expression of their target genes.

The main binding partners of transcriptionally active YAP and TAZ in the nucleus are TEA domain (TEAD) transcription factors (112). They mediate the majority of proliferative and oncogenic functions of YAP and TAZ (13, 113, 114). The TEAD family of transcription factors consists of four highly homologous proteins in humans and mice. TEAD1 is expressed in most adult tissues, while the expression of the other members of the protein family varies considerably between different tissues and developmental stages (115). All TEADs share almost identical DNA-binding domains and seem to bind to the same DNA binding motif with comparable affinity (115). However, binding to different TEAD proteins may explain at least some of the tissue-specific outcomes that are observed upon YAP/TAZ activation.

Overexpression studies lead to the identification of an array of YAP and TAZ transcriptional targets, including *CTGF*, *CYR61*, *BIRC5*, *AREG*, and others. These genes are considered as canonical target genes and are used as a readout of YAP/TAZ activity (116, 117). Additionally, YAP/TAZ or TEAD target gene signatures have been identified *in vitro* and *in vivo* in different cells and organs (4, 5, 118). However, these gene signatures rely on overexpression studies and only identify upregulated genes in general that might not represent direct transcriptional targets. Additionally, a substantial number of identified target genes seem to be expressed in a tissue-specific fashion. Additional ChIP-seq analyses in different tissue contexts are required to identify transcriptional programs directly regulated by YAP/TAZ-TEAD complexes.

Among the known transcriptional targets of YAP/TAZ and TEAD, several pro-proliferative target genes have been identified. However, the profound proliferation response upon activation of downstream Hippo effectors suggests that a larger transcriptional

**Figure 3.** Interconnections between the Hippo and RB/E2F pathways. A, common regulation of cell-cycle genes by YAP/TAZ-TEAD and activating E2F transcription factors. B, negative regulation of cell-cycle gene transcription by LATS1/2 through activation of the repressive DREAM complex. C, regulation of osteogenic differentiation by TAZ and RB through activation of RUNX2 transcription factors.



program exists to promote cell division. A study in p53-deficient breast cancer suggested a link between deregulated RB/E2F activity and YAP (119), but the molecular basis for the synergy between E2F transcription factors and YAP remained unknown until recently.

In quiescent cells, the Retinoblastoma (RB) family proteins—RB, p107, and p130—bind to and inhibit activating E2F transcription factors to restrict cell-cycle entry. This G<sub>1</sub>-S restriction point is released upon phosphorylation of RB family proteins by the cyclin-dependent kinases CDK4 and CDK6. Phosphorylated RB dissociates from activating E2F proteins that can now initiate the transcription of a plethora of target genes to trigger S phase entry and govern the transition through subsequent phases of the cell cycle (120, 121). Deregulation of RB/E2F activity is observed in the large majority of human cancers, either by loss or mutation of RB or by other means that interfere with functional retinoblastoma signaling, such as inactivation of cyclin-dependent kinase inhibitors (122, 123). In addition to cell-cycle control, the RB pathway is involved in the regulation of stem cell maintenance and differentiation. Inactivation of RB can lead to the expansion of stem cell populations and to lineage-specific differentiation defects (124), and at least to some extent these functions seem to depend on E2F activity.

Aside from the functional similarity between E2F and YAP/TAZ-mediated transcription—that is without doubt shared by other pro-proliferative transcription factors—the promoters of at least some genes have been reported as targets of both E2F and

TEAD transcription factors, such as *BIRC5* (Survivin; ref. 125) and *c-MYC* (4, 126, 127). We and others have shown that E2F and YAP/TEAD coordinately regulate a transcriptional program in cell-cycle control in mammalian cells (23, 128, 129), a function that is conserved in *Drosophila* (Fig. 3A; ref. 130).

YAP/TAZ-dependent gene transcription in oral squamous cell carcinoma cells is enriched for cell-cycle genes controlled by E2F, suggestive of a common mechanism of these transcription factors to overcome cell-cycle checkpoints (129). In hepatocytes, unrestricted E2F activity in mice with hepatic inactivation of all three RB family members leads to cell-cycle entry. However, inactivation and downregulation of YAP and TEAD1 counteracts the proliferative response in this model and is associated with reduced expression of E2F target genes and ultimately induction of complete cell-cycle arrest (128). In pancreatic cancer, where activation of YAP can compensate for loss of oncogenic KRAS to maintain tumor cell proliferation independent of the KRAS signaling cascade, YAP/TEAD2 and E2F1 coordinately bind to several cell-cycle-associated target genes in YAP-activated tumors (23). Importantly, YAP-driven proliferation is abolished in the presence of inactive E2F (23).

Mechanistically, several genes specifically upregulated in YAP-activated tumors exhibit binding sites for both YAP/TEAD2 and E2F1. Binding of E2F1, YAP, and/or TEAD2, respectively, to the same promoter fragments of canonical cell-cycle genes such as *Mcm3*, *Mcm6*, *Cdk1*, and *PolA1* could be shown by chromatin immunoprecipitation *in vivo* and *in vitro* (Fig. 3A; refs. 23, 128).

Additionally, bioinformatics analysis revealed that transcriptional start sites of YAP targets in the liver (4, 5) overlap with E2F ChIP-seq peaks in more than 60% of genes (128). Promoters of genes specifically upregulated in YAP-activated pancreatic cancer are enriched for E2F motif containing gene signatures (23). However, it remains to be investigated if E2F and YAP/TEAD directly bind to each other in the coordinate regulation of cell-cycle genes or if they are at least part of a common regulatory complex. An alternative explanation for the synergy of YAP/TAZ and E2F is that YAP/TAZ-TEAD in conjunction with AP-1 bind to more distant enhancers of E2F-regulated cell-cycle genes to promote proliferation (131). Independent of the direct molecular mechanism, the common activation of pro-proliferative target genes by E2F and YAP/TEAD transcription factors is likely to play a central role in the oncogenic function of the YAP transcriptional cofactor.

A recent study in endothelial cells showed that YAP might play in role in the regulation of S-phase entry (132). They authors identified several differential regulated genes in YAP knockdown cells that are part of the replication machinery, such as *CDC6*, *CDT1*, *MCM4*, and *MCM10* (132). The possibility of direct YAP binding to the promoter of these genes as well as the transcription factors involved remains to be investigated. Interestingly, a number differentially regulated S-phase genes also present E2F target genes in line with E2F requirement for S-phase progression (133). Beyond S-phase entry and progression, there is increasing evidence that the Hippo pathway is involved in the regulation of the G<sub>2</sub>-M phase (134). However, these functions seem to be independent of the Hippo downstream effectors YAP and TAZ and mainly mediated by MST1/2 and NDR kinases (reviewed in ref. 134). Additionally, LATS2 seems to be required for mitotic progression and cytokinesis (135). Some of the cell-cycle functions of the Hippo pathway may also be linked to interactions with transcriptional complexes such as the DREAM complex (dimerization partner, RB-like, E2F and multi-vulval class B; ref. 136) and related complexes involved at various steps of cell-cycle progression. In particular, LATS2 has been shown to phosphorylate DYRK to promote the assembly of the DREAM repressor complex at promoters of E2F-regulated cell-cycle genes (136), providing an additional level of cell-cycle control by upstream Hippo kinases (Fig. 3B).

In summary, an important role of YAP/TAZ-induced proliferation might be transcriptional activation of cell-cycle genes in a TEAD- and maybe also E2F-dependent fashion. However, further research is needed to understand the interplay between the cell-cycle regulation machinery and Hippo pathway components.

In addition to direct control of the cell cycle, YAP and TAZ can probably influence cell proliferation less directly by transcriptional regulation of several pathways that promote growth, cell divisions, and other pro-oncogenic functions. In the liver, a complex of YAP and TEAD4 directly targets *JAG1* and *NOTCH2* genes for transcriptional activation (27, 50). Recent data indicate that YAP-mediated activation of Notch signaling can differentiate mature hepatocytes into cells with characteristics of liver progenitor cells and propagate their expansion (27). In hepatocellular carcinoma, activation of YAP directly targets Notch signaling and is correlated with shorter survival times in human patients (50). In addition to Notch signaling, YAP as well as TAZ can activate the EGFR signaling axis by targeting the promoter of the amphiregulin (*AREG*) gene (57, 137). In breast cancer cells, this activation contributes to cell proliferation and migration independent of EGF (137). Thus, many transcriptional targets of YAP and TAZ

work together to promote proliferation by directly activating genes important in cell division and simultaneously targeting other pro-proliferative signaling pathways, such as Notch and EGFR, to sustain a robust proliferative response.

## Transcriptional Regulation by YAP/TAZ beyond TEAD

In addition to TEADs, several other transcriptional binding partners of YAP and TAZ have been identified. Interestingly, binding to transcription factors other than TEADs seem to mediate functions different from proliferation in many cases.

Both activated YAP and TAZ have been reported to bind to SMAD proteins to promote signaling from TGF $\beta$  and BMP pathways, adding another level to promote proliferation and oncogenic signaling (12, 138). On the other hand, phosphorylated and transcriptionally inactive YAP/TAZ can bind and retain SMAD2/3 proteins in the cytoplasm, inhibit their transcriptional activity, and induce their sequestration (12). Recently, YAP has been shown to interact with the AP-1 transcription factor family member FOS to promote epithelial-mesenchymal transition (EMT) and metastasis (139). In models of KRAS-driven lung and colorectal cancer, activation of YAP mediates resistance to inactivation of oncogenic KRAS, highlighting its role in tumor plasticity. Mechanistically, both KRAS and YAP converge on the transcription factor FOS to activate transcriptional targets that are involved in EMT, such as *Vimentin*, *Slug*, and *Snail* (139).

Although nuclear YAP/TAZ play important roles in oncogenic proliferation and EMT, they can also trigger expression of proapoptotic genes to counteract tumorigenesis. In DNA damage, YAP can interact with and stabilize p73 to enhance the apoptosis response (140). The interaction with p73 is greatly amplified by YAP tyrosine phosphorylation that is induced by c-ABL upon DNA damage (105). This mechanism presents an important system to divert YAP transcriptional control away from proliferation in the context of DNA damage. Interestingly, YAP is down-regulated in several hematologic malignancies with activated DNA damage signaling and high nuclear c-ABL kinase activity (141). Restoration of YAP activity in these tumor cells by inhibition of the upstream Hippo MST1 kinase is sufficient to drive them into apoptosis (141). Therefore, YAP phosphorylation by the Hippo core kinase cascade may not only exert tumor-suppressive functions, but may be oncogenic under certain conditions (Fig. 2). In addition to upstream Hippo kinases, AKT can phosphorylate YAP on Ser127 to inhibit the proapoptotic synergy between YAP and p73 (91, 142).

Apart from the control of oncogenic signaling, YAP and TAZ play a role in differentiation in several organs. Although both transcriptional cofactors generally seem to drive cells toward a more stem cell-like phenotype (6, 18, 143), they can also induce lineage-specific differentiation. TAZ interacts with RUNX2 to coactivate RUNX2-dependent gene transcription and direct mesenchymal stem cells toward osteogenic differentiation (144). At the same time, TAZ inhibits PPAR $\gamma$ -dependent gene expression and adipogenic differentiation (144). Interestingly, similar effects have been reported for phosphorylated RB that can bind to RUNX2 to promote osteogenic differentiation and can inhibit PPAR $\gamma$ -driven adipogenic differentiation in binding to E2Fs (145), presenting another example for functional convergence of Hippo and RB/E2F signaling (Fig. 3C). Besides RUNX2, several other developmental transcription factors are bound by the



Hippo signaling downstream effectors. YAP and TAZ both coactivate PAX3, a transcription factor important in the development of the neuronal crest (146), as well as TBX5, which initiates transcriptional programs in heart development (147). Additionally, a transcriptional complex of  $\beta$ -catenin–YAP–TBX5 is required for the maintenance of  $\beta$ -catenin–driven cancers and can bind to pro-proliferative target genes independent of TEAD transcription factors (90). In the intestine, YAP/TAZ cooperate with KLF4 in promoting differentiation into goblet cells (38). In addition to direct binding of transcription factors involved in development and differentiation, a complex of YAP and TEAD2 has been reported to influence the binding of HNF4 $\alpha$  and FOXA2 to enhancers of specific target genes in embryonic liver (148). Although this YAP/TEAD2-induced target gene switch likely involves direct binding to DNA, it remains unclear to date if the YAP/TEAD complex might be part of a larger transcriptional complex with FOXA2 or HNF4 $\alpha$ .

It is highly likely that the number of developmental transcription factors identified as binding partners of YAP and TAZ will be expanding in the future. Even from what we know to date it is obvious that the Hippo downstream effectors have a key role in development to promote differentiation into distinct cellular lineages dependent on the transcriptional binding partner.

## Targeting Hippo Signaling

An increasing amount of data highlights the important role of Hippo signaling in the control of proliferation, including unrestricted proliferation found in cancer. Inhibiting oncogenic YAP and TAZ to control proliferation is therefore a promising approach in cancers that show increased activity of these transcriptional cofactors. Additionally, YAP has been shown to be a critical mediator of Ras-driven cancer and to mediate resistance to suppression of RAS and RAF signaling and could therefore be used in combination therapy with inhibitors of these oncogenic pathways to prevent or break drug resistance (23, 139, 149, 150).

Several different mechanisms are known to activate YAP and TAZ in human cancers to promote proliferation, including genetic amplification of YAP or genetic inactivation of upstream Hippo regulators such as *LATS1*, *SAV1*, *NF2*, or GPCRs (reviewed in ref. 151). Additionally, input signals from other pathways (e.g., Wnt) are likely involved in deregulation of Hippo signaling. However, all these different effects on Hippo signaling converge onto one specific outcome: activation of YAP and/or TAZ to promote tumorigenesis. It therefore seems logical to target these downstream effectors directly to inhibit tumor development. Although YAP/TAZ bind to different transcription factors, their interaction with TEADs is likely the most important one in carcinogenesis as it promotes proliferation as well as metastasis (13, 114, 118, 152). Efforts to find specific inhibitors of YAP/TAZ–TEAD function have led to the identification of verteporfin. The compound was identified in a drug-screening approach and scored together with other porphyrins in inhibiting the interaction between YAP and TEAD (114). Most importantly, verteporfin also inhibits proliferation and liver overgrowth *in vivo* in mouse models with either YAP overexpression or inactivation of upstream *Nf2*/Merlin, resulting in disinhibition of endogenous YAP (114). An antitumorigenic effect of verteporfin was shown *in vitro*, where the drug was able to block tumor growth in uveal melanoma cells exhibiting activated YAP (53). Therefore, verteporfin could present a promising agent in the treatment of cancers

dependent on high YAP activity. However, as a drug used as a photosensitizer in photodynamic therapy for macular degeneration the phototoxic properties of verteporfin are likely to limit its application in a therapeutic setting. The development of alternative compounds that specifically inhibit the interaction between YAP/TAZ and TEAD is therefore of high interest in cancer therapy. In this line, several alternative approaches were described recently. Engineered YAP-like peptides are able to disrupt the YAP–TEAD interaction *in vitro* (153). However, their efficiency to target the transcriptional complex *in vivo* remains unclear to date. Another option to target YAP–TEAD-induced transcription might be by mimicking the interaction between vestigial-like proteins (VGLL) and TEADs. As alternative binding partners for TEAD transcription factors that compete with YAP for the same binding sites VGLL proteins counteract the activity of the Hippo downstream effectors at least in some tissues. VGLL4 has recently been identified as a tumor suppressor in lung cancer, where the transcriptional cofactor negatively regulates YAP–TEAD activity (154). A peptide mimicking VGLL4 function was reported to inhibit growths of gastric cancer cells *in vitro* and *in vivo* and to restrain tumor development in a *Helicobacter pylori* mouse model of gastric cancer (155). Even though the effects to VGLL4 might be tissue specific and need to be evaluated in other cancers, this novel peptide could present a promising option to inhibit YAP–TEAD-driven transcription in cancer.

Direct inhibition of YAP by genetic targeting was effective in an *in vivo* HCC model with deregulated Hippo signaling: in *Mst1/2*-conditional knockout mice, small interfering RNA-lipid nanoparticles targeting YAP were able to significantly reduce tumor burden in comparison to controls (156). Although this method did not specifically inhibit the YAP/TEAD interaction, transcriptional programs that are likely dependent on TEAD were significantly altered in this model, including E2F target genes (23, 128), as well as targets of HNF4 $\alpha$  and FOXA2 (153).

In addition to direct inhibition of YAP and TAZ transcriptional activity, modifying upstream Hippo signaling could present another approach to restrict, or activate, YAP/TAZ function. The identification of specific receptors that regulate Hippo signaling such as GPCR and EGFR (51, 56, 58) offers novel opportunities to functionally target this pathway. However, these receptors are mostly not pathway specific, and the complexity of signaling networks that are influenced for example even by a single member of the GPCR receptor family might limit this therapeutic approach. Additionally, dependent on the cellular context, the outcomes of YAP/TAZ inhibition might vary. This is of high importance in cancers where the transcriptional cofactors also might have a tumor-suppressive role (Fig. 2), such as in some hematologic malignancies where YAP promotes apoptosis (141). Additionally, the role of YAP in breast cancer remains controversial and the protein might act as a tumor suppressor possibly in the presence of additional genetic changes (157, 158). In the intestine, YAP can function to restrict the expansion of intestinal stem cells and to inhibit the growth of colorectal carcinoma xenografts (44). However, from what we know to date, these tumor suppressor functions may not depend on the interaction between YAP/TAZ and TEAD. Instead, they do at least in part depend on interaction with other transcription factors such as p73 in the apoptotic response (141) or KLF4 and RUNX2 in the induction of differentiation (38, 144). Additionally, the tumor-suppressive activity can be independent of any transcriptional activity at all and stem from functions specific to cytoplasmic YAP

(44). Given the multitude of interactions of Hippo signaling with different pathways and the diverse functions of YAP/TAZ, it seems to be the safest and most predictable approach to target the interaction with TEAD transcription factors to inhibit proliferation and other oncogenic effects in cancer. However, further studies have to show the efficiency and feasibility of this approach in a clinical setting.

It is also worth considering the possibility to inhibit Hippo pathway function to enhance the activity of YAP and TAZ. Applications for this approach include c-ABL–driven malignancies, to promote the induction of an apoptotic response dependent on a YAP/TAZ interaction with p73 (141) as well as targeting Hippo signaling functions beyond cancer. This is of special interest in organs where high YAP/TAZ activity is associated with tissue growth and regeneration, such as the heart (45, 159) or the liver (160, 161). Specific receptors such as GPCRs are the most promising targets to dampen the activity of upstream Hippo kinases: at least *in vitro*, GPCR ligands such as LPA promote the activity of YAP and TAZ (51). However, a large number of different GPCRs exist and the effects on the Hippo pathway differ in quality, dependent on the class of GPCR, as well as in quantity (51). Therefore, further research is needed to identify specific and ligands to effectively inhibit Hippo signaling upstream of YAP/TAZ, especially *in vivo*. Even if we succeed to successfully induce YAP/TAZ activation, the pro-oncogenic side effects associated with any drug that promotes proliferation should be considered carefully—even when the treatment is only given for a short period of time.

## Conclusion

There has been an explosion of reports on the Hippo/YAP pathway in the past few years. These studies have brought this signaling pathway to the forefront of cancer research. Similar to other key cancer pathways, the Hippo/YAP pathway is complex and coordinates multiple cellular functions, including proliferation, cell death, and differentiation. This plethora of functions and

recent evidence strongly indicate that the Hippo/YAP pathway is a central player in tumor plasticity and how cycling cells interact with their environment. Superficially, the Hippo/YAP pathway seems to serve similar functions to other central pathways such as the Rb/E2F pathway. However, accumulating evidence points to unique functions for this pathway, even though the basis of this specificity is still not fully understood. A key aspect of the Hippo/YAP pathway may be its ability to sense and mediate unique extracellular signals, including mechanical forces. The Hippo/YAP pathway can be both tumor suppressive and oncogenic, and it will be key in the future to better understand the tissue specificity of action of this pathway, as well as cell-intrinsic and non-cell-autonomous effects on cell proliferation. This will be crucial before anticancer therapies targeting this pathway can be implemented. However, early success repurposing a drug such as verteporfin to regulate the Hippo pathway suggests that, in the future, this pathway is "druggable" and may thus expand therapeutic options in cancer patients.

## Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

## Acknowledgments

The authors thank M. Butte and P. Mazur for their input on the manuscript and apologize to the authors for their work not being cited owing to space limitations.

## Grant Support

This work was supported by the NIH (grant CA114102 to J. Sage), the Lucile Packard Foundation for Children's Health (Ernest and Amelia Gallo Endowed Postdoctoral Fellowship CTSA grant number UL1 RR025744 to U. Ehmer), and the Dr. Mildred Scheel fellowship from Deutsche Krebshilfe (to U. Ehmer). Dr. Sage is the Harriet and Mary Zelencik Scientist in Children's Cancer and Blood Diseases.

Received July 10, 2015; revised September 8, 2015; accepted September 25, 2015; published OnlineFirst October 2, 2015.

## References

- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011;144:646–74.
- Wu S, Huang J, Dong J, Pan D. hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. *Cell* 2003;114:445–56.
- Harvey KF, Pflieger CM, Hariharan IK. The *Drosophila* Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. *Cell* 2003;114:457–67.
- Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a universal size-control mechanism in *Drosophila* and mammals. *Cell* 2007;130:1120–33.
- Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. *Genes Dev* 2007;21:2747–61.
- Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu J, et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. *Genes Dev* 2010;24:1106–18.
- Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. *Nat Cell Biol* 2014;16:357–66.
- Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the *Drosophila* homolog of YAP. *Cell* 2005;122:421–34.
- Badouel C, Garg A, McNeill H. Herding Hippos: regulating growth in flies and man. *Curr Opin Cell Biol* 2009;21:837–43.
- Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. *EMBO J* 2000;19:6778–91.
- Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, et al. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. *Cell* 2014;158:157–70.
- Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, Larsen BG, et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway. *Dev Cell* 2010;19:831–44.
- Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAP-dependent gene induction and growth control. *Genes Dev* 2008;22:1962–71.
- Yu FX, Guan KL. The Hippo pathway: regulators and regulations. *Genes Dev* 2013;27:355–71.
- Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. *Cancer Cell* 2009;16:425–38.
- Schlegelmilch K, Mohseni M, Kirak O, Pruszk J, Rodriguez JR, Zhou D, et al. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. *Cell* 2011;144:782–95.
- Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. *Cancer Cell* 2014;25:831–45.

18. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. *Cell* 2011;147:759–72.
19. Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V, et al. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. *J Invest Dermatol* 2014;134:123–32.
20. Bhat KP, Salazar KL, Balasubramanian V, Wani K, Heathcock L, Hollingsworth F, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. *Genes Dev* 2011;25:2594–609.
21. Wang Y, Dong Q, Zhang Q, Li Z, Wang E, Qiu X. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. *Cancer Sci* 2010;101:1279–85.
22. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. *Nat Rev Cancer* 2013;13:246–57.
23. Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. *Cell* 2014;158:185–97.
24. Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* 2015;517:576–82.
25. Dhanasekaran SM, Balbin OA, Chen G, Nadal E, Kalyana-Sundaram S, Pan J, et al. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. *Nat Commun* 2014;5:5893.
26. Seidel C, Schagdarsurengin U, Blumke K, Wurl P, Pfeifer GP, Hauptmann S, et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. *Mol Carcinog* 2007;46:865–71.
27. Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe-Mooney B, Gurung B, et al. Hippo pathway activity influences liver cell fate. *Cell* 2014;157:1324–38.
28. Karpowicz P, Perez J, Perrimon N. The Hippo tumor suppressor pathway regulates intestinal stem cell regeneration. *Development* 2010;137:4135–45.
29. Cai J, Zhang N, Zheng Y, de Wilde RF, Maitra A, Pan D. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. *Genes Dev* 2010;24:2383–8.
30. Judson RN, Tremblay AM, Knopp P, White RB, Urcia R, De Bari C, et al. The Hippo pathway member Yap plays a key role in influencing fate decisions in muscle satellite cells. *J Cell Sci* 2012;125:6009–19.
31. Gao T, Zhou D, Yang C, Singh T, Penzo-Mendez A, Maddipati R, et al. Hippo signaling regulates differentiation and maintenance in the exocrine pancreas. *Gastroenterology* 2013;144:1543–53, 53.e1.
32. Mahoney JE, Mori M, Szymaniak AD, Varelas X, Cardoso WV. The hippo pathway effector Yap controls patterning and differentiation of airway epithelial progenitors. *Dev Cell* 2014;30:137–50.
33. Lee MJ, Ran Byun M, Furutani-Seiki M, Hong JH, Jung HS. YAP and TAZ regulate skin wound healing. *J Invest Dermatol* 2014;134:518–25.
34. Morin-Kensicki EM, Boone BN, Howell M, Stonebraker JR, Teed J, Alb JG, et al. Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. *Mol Cell Biol* 2006;26:77–87.
35. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, et al. Hippo signaling is a potent *in vivo* growth and tumor suppressor pathway in the mammalian liver. *Proc Natl Acad Sci U S A* 2010;107:1437–42.
36. Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, et al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. *Proc Natl Acad Sci U S A* 2010;107:8248–53.
37. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. *Curr Biol* 2007;17:2054–60.
38. Imajo M, Ebisuya M, Nishida E. Dual role of YAP and TAZ in renewal of the intestinal epithelium. *Nat Cell Biol* 2015;17:7–19.
39. Cao X, Pfaff SL, Gage FH. YAP regulates neural progenitor cell number via the TEA domain transcription factor. *Genes Dev* 2008;22:3320–34.
40. Lee JH, Kim TS, Yang TH, Koo BK, Oh SP, Lee KP, et al. A crucial role of WW45 in developing epithelial tissues in the mouse. *EMBO J* 2008;27:1231–42.
41. Seo E, Basu-Roy U, Gunaratne PH, Coarfa C, Lim DS, Basilico C, et al. SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage. *Cell Rep* 2013;3:2075–87.
42. Zhao R, Fallon TR, Saladi SV, Pardo-Saganta A, Villoria J, Mou H, et al. Yap tunes airway epithelial size and architecture by regulating the identity, maintenance, and self-renewal of stem cells. *Dev Cell* 2014;30:151–65.
43. Sarikaya DP, Extavour CG. The Hippo pathway regulates homeostatic growth of stem cell niche precursors in the Drosophila ovary. *PLoS Genet* 2015;11:e1004962.
44. Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. *Nature* 2013;493:106–10.
45. Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson RL, et al. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. *Science* 2011;332:458–61.
46. Varelas X, Miller BW, Sopko R, Song S, Gregorieff A, Fellouse FA, et al. The Hippo pathway regulates Wnt/beta-catenin signaling. *Dev Cell* 2010;18:579–91.
47. Hergovich A, Hemmings BA. TAZ-mediated crosstalk between Wnt and Hippo signaling. *Dev Cell* 2010;18:508–9.
48. Strassburger K, Tiebe M, Pinna F, Breuhahn K, Teleman AA. Insulin/IGF signaling drives cell proliferation in part via Yorkie/YAP. *Dev Biol* 2012;367:187–96.
49. Fernandez LA, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S, et al. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. *Genes Dev* 2009;23:2729–41.
50. Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. *Gastroenterology* 2013;144:1530–42 e12.
51. Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. *Cell* 2012;150:780–91.
52. Miller E, Yang J, DeRan M, Wu C, Su AI, Bonamy GM, et al. Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. *Chem Biol* 2012;19:955–62.
53. Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. *Cancer Cell* 2014;25:822–30.
54. Mo JS, Yu FX, Gong R, Brown JH, Guan KL. Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). *Genes Dev* 2012;26:2138–43.
55. Fan R, Kim NG, Gumbiner BM. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. *Proc Natl Acad Sci U S A* 2013;110:2569–74.
56. Reddy BV, Irvine KD. Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins. *Dev Cell* 2013;24:459–71.
57. Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R, et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. *Nat Cell Biol* 2009;11:1444–50.
58. Haskins JW, Nguyen DX, Stern DF. Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration. *Sci Signal* 2014;7:ra116.
59. Guo X, Zhao B. Integration of mechanical and chemical signals by YAP and TAZ transcription coactivators. *Cell Biosci* 2013;3:33.
60. Low BC, Pan CQ, Shivashankar GV, Bershadsky A, Sudol M, Sheetz M. YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth. *FEBS Lett* 2014;588:2663–70.
61. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of YAP/TAZ in mechanotransduction. *Nature* 2011;474:179–83.
62. Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N, et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. *Cell* 2013;154:1047–59.
63. Mana-Capelli S, Paramasivam M, Dutta S, McCollum D. Angiomotins link F-actin architecture to Hippo pathway signaling. *Mol Biol Cell* 2014;25:1676–85.
64. Mohseni M, Sun J, Lau A, Curtis S, Goldsmith J, Fox VL, et al. A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. *Nat Cell Biol* 2014;16:108–17.

65. Ganem NJ, Cornils H, Chiu SY, O'Rourke KP, Arnaud J, Yimlamai D, et al. Cytokinesis failure triggers hippo tumor suppressor pathway activation. *Cell* 2014;158:833–48.
66. Deng H, Wang W, Yu J, Zheng Y, Qing Y, Pan D. Spectrin regulates Hippo signaling by modulating cortical actomyosin activity. *Elife* 2015;4:e06567.
67. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. *Nat Rev Mol Cell Biol* 2014;15:786–801.
68. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. *Cell* 2009;139:891–906.
69. Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. *Nat Cell Biol* 2013;15:637–46.
70. Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, Tao C, et al. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. *Nat Cell Biol* 2006;8:27–36.
71. Yu J, Zheng Y, Dong J, Klusza S, Deng WM, Pan D. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. *Dev Cell* 2010;18:288–99.
72. Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. *Genes Dev* 2011;25:51–63.
73. Kim NG, Koh E, Chen X, Gumbiner BM. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. *Proc Natl Acad Sci U S A* 2011;108:11930–5.
74. Martin-Belmonte F, Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. *Nat Rev Cancer* 2012;12:23–38.
75. Cooper J, Giancotti FG. Molecular insights into NF2/Merlin tumor suppressor function. *FEBS Lett* 2014;588:2743–52.
76. Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. *Cell* 2013;154:1342–55.
77. Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4 (DCAF1) in the nucleus. *Cell* 2010;140:477–90.
78. Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zagzag D, et al. Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. *Cancer Cell* 2014;26:48–60.
79. Benhamouche S, Curto M, Saotome I, Gladden AB, Liu CH, Giovannini M, et al. NF2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. *Genes Dev* 2010;24:1718–30.
80. Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. *Dev Cell* 2010;19:27–38.
81. Moleirinho S, Guerrant W, Kissil JL. The Angiomotins—from discovery to function. *FEBS Lett* 2014;588:2693–703.
82. Chan SW, Lim CJ, Guo F, Tan I, Leung T, Hong W. Actin-binding and cell proliferation activities of angiomotin family members are regulated by Hippo pathway-mediated phosphorylation. *J Biol Chem* 2013;288:37296–307.
83. Dai X, She P, Chi F, Feng Y, Liu H, Jin D, et al. Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis. *J Biol Chem* 2013;288:34041–51.
84. Adler JJ, Johnson DE, Heller BL, Bringman LR, Ranahan WP, Conwell MD, et al. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases. *Proc Natl Acad Sci U S A* 2013;110:17368–73.
85. Li J, Gao E, Vite A, Yi R, Gomez L, Goossens S, et al. Alpha-catenins control cardiomyocyte proliferation by regulating yap activity. *Circ Res* 2015;116:70–9.
86. Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. *Nat Rev Drug Discov* 2014;13:63–79.
87. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. *Cell* 2012;149:1192–205.
88. Azzolin L, Zanconato F, Bresolin S, Forcato M, Basso G, Biciato S, et al. Role of TAZ as mediator of Wnt signaling. *Cell* 2012;151:1443–56.
89. Imajo M, Miyatake K, Iimura A, Miyamoto A, Nishida E. A molecular mechanism that links Hippo signalling to the inhibition of Wnt/beta-catenin signalling. *EMBO J* 2012;31:1109–22.
90. Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ, et al. beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. *Cell* 2012;151:1457–73.
91. Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. *Mol Cell* 2003;11:11–23.
92. Lin Z, Zhou P, von Gise A, Gu F, Ma Q, Chen J, et al. Pi3kcb links Hippo-YAP and PI3K-AKT signaling pathways to promote cardiomyocyte proliferation and survival. *Circ Res* 2015;116:35–45.
93. Xin M, Kim Y, Sutherland LB, Murakami M, Qi X, McAnally J, et al. Hippo pathway effector Yap promotes cardiac regeneration. *Proc Natl Acad Sci U S A* 2013;110:13839–44.
94. Yamamoto S, Yang G, Zablocki D, Liu J, Hong C, Kim SJ, et al. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. *J Clin Invest* 2003;111:1463–74.
95. Liang N, Zhang C, Dill P, Panasyuk G, Pion D, Koka V, et al. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. *J Exp Med* 2014;211:2249–63.
96. Zhou D, Zhang Y, Wu H, Barry E, Yin Y, Lawrence E, et al. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. *Proc Natl Acad Sci U S A* 2011;108:E1312–20.
97. Rayon T, Menchero S, Nieto A, Xenopoulos P, Crespo M, Cockburn K, et al. Notch and hippo converge on Cdx2 to specify the proctoderm lineage in the mouse blastocyst. *Dev Cell* 2014;30:410–22.
98. Djiane A, Zaessinger S, Babaoglan AB, Bray SJ. Notch inhibits Yorkie activity in Drosophila wing discs. *PLoS One* 2014;9:e106211.
99. Tariki M, Dhanyamraju PK, Fendrich V, Borggrete T, Feldmann G, Lauth M. The Yes-associated protein controls the cell density regulation of Hedgehog signaling. *Oncogenesis* 2014;3:e112.
100. Kim M, Kim M, Lee MS, Kim CH, Lim DS. The MST1/2-SAV1 complex of the Hippo pathway promotes ciliogenesis. *Nat Commun* 2014;5:5370.
101. Kim J, Jo H, Hong H, Kim MH, Kim JM, Lee JK, et al. Actin remodelling factors control ciliogenesis by regulating YAP/TAZ activity and vesicle trafficking. *Nat Commun* 2015;6:6781.
102. Tomlinson V, Gudmundsdottir K, Luong P, Leung KY, Knebel A, Basu S. JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis. *Cell Death Dis* 2010;1:e29.
103. Oudhoff MJ, Freeman SA, Couzens AL, Antignano F, Kuznetsova E, Min PH, et al. Control of the hippo pathway by Set7-dependent methylation of Yap. *Dev Cell* 2013;26:188–94.
104. Zaidi SK, Sullivan AJ, Medina R, Ito Y, van Wijnen AJ, Stein JL, et al. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. *EMBO J* 2004;23:790–9.
105. Levy D, Adamovich Y, Reuven N, Shaul Y. Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. *Mol Cell* 2008;29:350–61.
106. Keshet R, Adler J, Ricardo Lax I, Shanzer M, Porat Z, Reuven N, et al. c-Abl antagonizes the YAP oncogenic function. *Cell Death Differ* 2015;22:935–45.
107. Liu CY, Lv X, Li T, Xu Y, Zhou X, Zhao S, et al. PP1 cooperates with ASPP2 to dephosphorylate and activate TAZ. *J Biol Chem* 2011;286:5558–66.
108. Wang P, Bai Y, Song B, Wang Y, Liu D, Lai Y, et al. PP1A-mediated dephosphorylation positively regulates YAP2 activity. *PLoS One* 2011;6:e24288.
109. Huang JM, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A, et al. YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. *Oncogene* 2013;32:2220–9.
110. Couzens AL, Knight JD, Kean MJ, Teo G, Weiss A, Dunham WH, et al. Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions. *Sci Signal* 2013;6:rs15.

111. Jung S, Kang JG, Lee JH, Song KJ, Ko JH, Kim YS. PHLPP1 regulates contact inhibition by dephosphorylating Mst1 at the inhibitory site. *Biochem Biophys Res Commun* 2014;443:1263–9.
112. Li Z, Zhao B, Wang P, Chen F, Dong Z, Yang H, et al. Structural insights into the YAP and TEAD complex. *Genes Dev* 2010;24:235–40.
113. Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong W. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. *J Biol Chem* 2009;284:14347–58.
114. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. *Genes Dev* 2012;26:1300–5.
115. Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. *Genes Dev* 2001;15:1229–41.
116. Urtasun R, Latasa MU, Demartis MI, Balzani S, Goni S, Garcia-Irigoyen O, et al. Connective tissue growth factor autocrine in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. *Hepatology* 2011;54:2149–58.
117. Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. *Physiol Rev* 2014;94:1287–312.
118. Ota M, Sasaki H. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. *Development* 2008;135:4059–69.
119. Cheng L, Zhou Z, Flesken-Nikitin A, Toshkov IA, Wang W, Camps J, et al. Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency. *Oncogene* 2010;29:5700–11.
120. Dick FA, Rubin SM. Molecular mechanisms underlying RB protein function. *Nat Rev Mol Cell Biol* 2013;14:297–306.
121. Weinberg RA. The retinoblastoma protein and cell cycle control. *Cell* 1995;81:323–30.
122. Burkhardt DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. *Nat Rev Cancer* 2008;8:671–82.
123. Viatour P, Sage J. Newly identified aspects of tumor suppression by RB. *Dis Models Mech* 2011;4:581–5.
124. Sage J. The retinoblastoma tumor suppressor and stem cell biology. *Genes Dev* 2012;26:1409–20.
125. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA. Aberrant regulation of survivin by the RB/E2F family of proteins. *J Biol Chem* 2004;279:40511–20.
126. Thalmeier K, Synovzik H, Mertz R, Winnacker EL, Lipp M. Nuclear factor E2F mediates basic transcription and trans-activation by E1a of the human MYC promoter. *Genes Dev* 1989;3:527–36.
127. Neto-Silva RM, de Beco S, Johnston LA. Evidence for a growth-stabilizing regulatory feedback mechanism between Myc and Yorkie, the *Drosophila* homolog of Yap. *Dev Cell* 2010;19:507–20.
128. Ehmer U, Zmoos AF, Auerbach RK, Vaka D, Butte AJ, Kay MA, et al. Organ size control is dominant over Rb family inactivation to restrict proliferation *in vivo*. *Cell Rep* 2014;8:371–81.
129. Hiemer SE, Zhang L, Kartha VK, Packer TS, Almershed M, Noonan V, et al. A YAP/TAZ-regulated molecular signature is associated with oral squamous cell carcinoma. *Mol Cancer Res* 2015;13:957–68.
130. Nicolay BN, Bayarmagnai B, Islam AB, Lopez-Bigas N, Frolov MV. Cooperation between dE2F1 and Yki/Sd defines a distinct transcriptional program necessary to bypass cell cycle exit. *Genes Dev* 2011;25:323–35.
131. Zancanato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B, et al. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. *Nat Cell Biol* 2015;17:1218–27.
132. Shen Z, Stanger BZ. YAP regulates S-phase entry in endothelial cells. *PLoS One* 2015;10:e0117522.
133. Mudryj M, Devoto SH, Hiebert SW, Hunter T, Pines J, Nevins JR. Cell cycle regulation of the E2F transcription factor involves an interaction with cyclin A. *Cell* 1991;65:1243–53.
134. Hergovich A, Hemmings BA. Hippo signalling in the G<sub>2</sub>/M cell cycle phase: lessons learned from the yeast MEN and SIN pathways. *Semin Cell Dev Biol* 2012;23:794–802.
135. Yabuta N, Okada N, Ito A, Hosomi T, Nishihara S, Sasayama Y, et al. Lats2 is an essential mitotic regulator required for the coordination of cell division. *J Biol Chem* 2007;282:19259–71.
136. Tschop K, Conery AR, Litovchick L, Decaprio JA, Settleman J, Harlow E, et al. A kinase shRNA screen links LATS2 and the pRB tumor suppressor. *Genes Dev* 2011;25:814–30.
137. Yang N, Morrison CD, Liu P, Miecznikowski J, Bshara W, Han S, et al. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. *Cell Cycle* 2012;11:2922–30.
138. Alarcon C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. *Cell* 2009;139:757–69.
139. Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. *Cell* 2014;158:171–84.
140. Strano S, Monti O, Pediconi N, Baccharini A, Fontemaggi G, Lapi E, et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. *Mol Cell* 2005;18:447–59.
141. Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. *Nat Med* 2014;20:599–606.
142. Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G, et al. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. *Mol Cell* 2008;32:803–14.
143. Mo JS, Park HW, Guan KL. The Hippo signaling pathway in stem cell biology and cancer. *EMBO Rep* 2014;15:642–56.
144. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. *Science* 2005;309:1074–8.
145. Calo E, Quintero-Estades JA, Danielian PS, Nedelcu S, Berman SD, Lees JA. Rb regulates fate choice and lineage commitment *in vivo*. *Nature* 2010;466:1110–4.
146. Manderfield LJ, Engleka KA, Aghajanian H, Gupta M, Yang S, Li L, et al. Pax3 and hippo signaling coordinate melanocyte gene expression in neural crest. *Cell Rep* 2014;9:1885–95.
147. Murakami M, Nakagawa M, Olson EN, Nakagawa O. A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. *Proc Natl Acad Sci U S A* 2005;102:18034–9.
148. Alder O, Cullum R, Lee S, Kan AC, Wei W, Yi Y, et al. Hippo signaling influences HNF4A and FOXA2 enhancer switching during hepatocyte differentiation. *Cell Rep* 2014;9:261–71.
149. Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. *Sci Signal* 2014;7:ra42.
150. Lin L, Sabnis AJ, Chan E, Olivares V, Cade L, Pazarentzos E, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. *Nat Genet* 2015;47:250–6.
151. Plouffe SW, Hong AW, Guan KL. Disease implications of the Hippo/YAP pathway. *Trends Mol Med* 2015;21:212–22.
152. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. *Proc Natl Acad Sci U S A* 2012;109:E2441–50.
153. Zhou Z, Hu T, Xu Z, Lin Z, Zhang Z, Feng T, et al. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides. *FASEB J* 2015;29:724–32.
154. Zhang W, Gao Y, Li P, Shi Z, Guo T, Li F, et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. *Cell Res* 2014;24:331–43.
155. Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. *Cancer Cell* 2014;25:166–80.
156. Fitamant J, Kottakis F, Benhamouche S, Tian HS, Chuvin N, Parachoniak CA, et al. YAP inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression. *Cell Rep* 2015 Mar 10. pii: S2211-1247(15)00173-4. doi: 10.1016/j.celrep.2015.02.027. [Epub ahead of print].

157. Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. *Cell Death Differ* 2008;15:1752–9.
158. Chen Q, Zhang N, Gray RS, Li H, Ewald AJ, Zahnow CA, et al. A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis. *Genes Dev* 2014;28:432–7.
159. von Gise A, Lin Z, Schlegelmilch K, Honor LB, Pan GM, Buck JN, et al. YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. *Proc Natl Acad Sci U S A* 2012;109:2394–9.
160. Grijalva JL, Huizenga M, Mueller K, Rodriguez S, Brazzo J, Camargo F, et al. Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration. *Am J Physiol Gastrointest Liver Physiol* 2014;307:G196–204.
161. Wang C, Zhang L, He Q, Feng X, Zhu J, Xu Z, et al. Differences in Yes-associated protein and mRNA levels in regenerating liver and hepatocellular carcinoma. *Mol Med Rep* 2012;5:410–4.
162. Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. *Nat Rev Cancer* 2015;15:73–9.